Last week, readers were most interested in a story about BD's plan to separate its Biosciences and Diagnostics Solutions business by the end of 2026.

Demand remains low, but lab stakeholders said the industry is significantly better prepared to meet a spike in H5N1 testing ...

The digital pathology software developer is raising funding that would help it to increase its headcount and support its Aiosyn Mitosis Breast application.

NEW YORK — MRC Holland said on Thursday that its blood-based assay for Temple, Kagami-Ogata, and Russell-Silver syndromes has received certification under Europe's In Vitro Diagnostic Regulation (IVDR ...

The Foundation Medicine next-generation sequencing-based panels use Fulgent's technology platform and will analyze genes associated with hereditary cancers.

Qiagen said the intellectual property in question covers technologies used in its QuantiFeron latent tuberculosis assays.

NEW YORK – UK-based startup Oxford Cancer Analytics is using the $11 million it has raised in a Series A financing to further develop and commercialize its protein-based lung cancer screening assay.

The deal will let ABL commercialize tests equivalent to those that had been offered by the shuttered Siemens subsidiary Fast Track Diagnostics.

The bank had suspended its rating and price target for Tempus during its $600 million acquisition of Ambry Genetics due to TD Securities' involvement in the deal.

Abbott also currently offers the FDA-cleared molecular Alinity M STI assay to detect and differentiate between Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma ...

The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.